HCW Biologics Inc. – NASDAQ:HCWB

Add to watchlist

$3.16

+2.74

+652.38%

Market closed

Open in 2 days

-35.09%

month

-35.09%

quarter

-61.82%

year

Market Cap	15.08M
Enterprise value	N/A

P/E	-3.51
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	5.25
Price/Book	1.44
PEG ratio	-0.17
EPS	-0.76

Revenue	3.92M
EBITDA	-26.23M
Income	-27.39M
Revenue Q/Q	2590.14%
Revenue Y/Y	7.68%

Profit margin	-198.85%
Oper. margin	-198.87%
Gross margin	44.13%
EBIT margin	-198.87%
EBITDA margin	-668.11%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

HCW Biologics Inc. (NASDAQ:HCWB): Profit margin
Jun 2023	622.80K	-4.30M	-691.13%
Sep 2023	853.10K	-4.93M	-578.9%
Dec 2023	1.32M	-10.68M	-806.69%
Mar 2024	1.12M	-7.46M	-662.82%

HCW Biologics Financials Estimate

Q Y

HCW Biologics Inc. (NASDAQ:HCWB): Analyst Estimates
2025	1.6M	-29.59M	-1849.94%
2026	900K	-38.47M	-4275.33%
2027	33.73M	-24.79M	-73.5%
2028	57.14M	-9.70M	-16.97%

Analysts Price target
Financials & Ratios estimates

HCW Biologics Inc. (NASDAQ:HCWB): Earnings per share (EPS)
2023-11-14	-0.13	-0.14
2024-04-01	-0.14	-0.3

HCW Biologics Inc. (NASDAQ:HCWB): Payout ratio
Payout ratio	0%

HCW Biologics Inc. (NASDAQ:HCWB): Dividend Yield
2019
2020
2021	3.4%
2022
2023

HCW Biologics Inc. (NASDAQ:HCWB): Debt to assets
Jun 2023	39483244	10.89M	27.6%
Sep 2023	35616342	11.74M	32.99%
Dec 2023	28513660	15.05M	52.79%
Mar 2024	30427656	21.68M	71.27%

HCW Biologics Inc. (NASDAQ:HCWB): Cash Flow
Jun 2023	-9.39M	-1.55M	7.71K
Sep 2023	-5.58M	9.36M	-8.89K
Dec 2023	-3.89M	-3.71M	-15.25K
Mar 2024	-3.60M	-129.70K	4.22M

HCW Biologics alternative data

HCW Biologics Inc. (NASDAQ:HCWB): Employee count
Aug 2023	44
Sep 2023	44
Oct 2023	44
Nov 2023	44
Dec 2023	44
Jan 2024	44
Feb 2024	44
Mar 2024	44
Apr 2024	44
May 2024	45
Jun 2024	45
Jul 2024	45

HCW Biologics
Hedge Funds Holdings Q1 2023

1.19% -0.99%

of HCWB is owned by hedge funds

7 -7

hedge funds hold HCWB stock

425.56K -355.45K

shares is hold by hedge funds

HCWB hedge funds holdings changes

HCW Biologics Inc. (NASDAQ:HCWB): Insider trades (number of shares)
Period	Buy	Sel
May 2023	104836	0
Jun 2023	95358	0
Sep 2023	5463	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	7 Sep 2023	WINER GARY M director director	Common Stock	63	$1.95	$123
Purchase	6 Sep 2023	BYAM REBECCA officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	5,000	$1.95	$9,750
Purchase	5 Sep 2023	WINER GARY M director director	Common Stock	400	$1.75	$700
Purchase	9 Jun 2023	BYAM REBECCA officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	20,000	$2.06	$41,280
Option	8 Jun 2023	FLOWERS LEE officer: SVP of Business Development officer: SVP of Business Develo..	Common Stock	5,356	$0.14	$750
Purchase	8 Jun 2023	FLOWERS LEE officer: SVP of Business Development officer: SVP of Business Develo..	Common Stock	10,000	$2.16	$21,570
Option	8 Jun 2023	FLOWERS LEE officer: SVP of Business Development officer: SVP of Business Develo..	Stock Option (Right to Buy)	5,356	$0.14	$750
Purchase	8 Jun 2023	BYAM REBECCA officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	4,696	$2.21	$10,388
Purchase	7 Jun 2023	BYAM REBECCA officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	20,000	$2.03	$40,640
Purchase	6 Jun 2023	BYAM REBECCA officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	19,062	$1.83	$34,788

Status	Patent	Filling date	Issue date
Application	Application METHODS OF TREATING AGING-RELATED DISORDERS Filling date: 1 Jun 2021 Issue date: 10 Mar 2022	1 Jun 2021	10 Mar 2022
Application	Application METHODS OF TREATING AGE-RELATED AND INFLAMMATORY DISEASES Filling date: 11 Feb 2021 Issue date: 4 Nov 2021	11 Feb 2021	4 Nov 2021
Application	Application CHROMATOGRAPHY RESIN AND USES THEREOF Filling date: 11 Feb 2021 Issue date: 9 Sep 2021	11 Feb 2021	9 Sep 2021
Application	Application METHODS OF ACTIVATING REGULATORY T CELLS Filling date: 11 Feb 2021 Issue date: 2 Sep 2021	11 Feb 2021	2 Sep 2021
Application	Application MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF Filling date: 19 Jun 2020 Issue date: 13 May 2021	19 Jun 2020	13 May 2021
Application	Application SINGLE-CHAIN AND MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF Filling date: 30 Aug 2019 Issue date: 8 Apr 2021	30 Aug 2019	8 Apr 2021
Application	Application MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF Filling date: 19 Nov 2020 Issue date: 11 Mar 2021	19 Nov 2020	11 Mar 2021
Application	Application MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF Filling date: 19 Nov 2020 Issue date: 11 Mar 2021	19 Nov 2020	11 Mar 2021
Application	Application METHODS OF TREATING AGING-RELATED DISORDERS Filling date: 30 Aug 2019 Issue date: 4 Mar 2021	30 Aug 2019	4 Mar 2021
Application	Application SINGLE-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF Filling date: 29 Aug 2019 Issue date: 18 Jun 2020	29 Aug 2019	18 Jun 2020

HCW Biologics
Executives

Insider	Age	Compensation
Dr. Hing C. Wong Ph.D. (1954) Founder, Chief Executive Officer, Director & Sec.	71	$374,400
Ms. Rebecca Byam CPA, M.B.A. (1956) Chief Financial Officer	69	$286,000
Dr. Peter Rhode (1958) Chief Scientific Officer & Vice President of Clinical Operations	67	$228,500

HCW Biologics
Latest News

Monday, 23 December 2024
08:10	HCW Biologics Inc. Received NASDAQ Staff Determination Letter	globenewswire.com
Monday, 18 November 2024
21:27	HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules	globenewswire.com
10:15	Why Is Penny Stock HCW Biologics Surging On Monday?	benzinga.com
07:00	HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate	globenewswire.com
Thursday, 14 November 2024
16:40	HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights	globenewswire.com
Friday, 23 August 2024
16:30	HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction	globenewswire.com
Wednesday, 14 August 2024
16:35	HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights	globenewswire.com
Wednesday, 15 May 2024
16:39	HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights	globenewswire.com
Monday, 1 April 2024
16:10	HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights	globenewswire.com
Tuesday, 14 November 2023
07:00	HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights	globenewswire.com
Wednesday, 8 November 2023
07:30	Investigator Sponsor of HCW Biologics' Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting	globenewswire.com
Wednesday, 1 November 2023
07:30	Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting	globenewswire.com
Wednesday, 31 August 2022
09:22	HCW Biologics Inc (HCWB), Quotient Technology (QUOT) – Smith Micro Software And 3 Other Stocks Under $3 Insiders Are Aggressively Buying	Benzinga
Thursday, 24 March 2022
08:00	HCW Biologics to Present at 2022 Virtual Growth Conference Sponsored by the Maxim Group and M-Vest	GlobeNewsWire
Monday, 24 January 2022
09:22	Masonic Cancer Center To Evaluate HCW Biologics' Bifunctional Fusion Protein In Advanced Cancers	Benzinga
Thursday, 20 January 2022
09:24	HCW Biologics Lead Candidate Shows Preclinical Anti-Tumor Activity, Reduced Side Effects of Chemo	Benzinga
Thursday, 28 October 2021
13:17	Good Penny Stocks to Buy Right Now? 3 to Watch in November	PennyStocks
Tuesday, 19 October 2021
12:37	Making a Penny Stocks Watchlist? Don't Forget These 3 Small-Caps	PennyStocks
Tuesday, 24 August 2021
07:32	HCW Biologics Showcases Scientific Paper in Molecular Therapy Highlighting Potential of HCW9218 as Novel, Bifunctional Cancer Immunotherapeutic	GlobeNewsWire
Tuesday, 17 August 2021
07:32	HCW Biologics' Article Published in Cancer Immunology Research Validates Novel Tissue Factor Scaffold Fusion Protein (TOBI™) Discovery Platform	GlobeNewsWire
Friday, 13 August 2021
07:10	HCW Biologics Reports Second Quarter Financial Results and Recent Business Highlights	GlobeNewsWire

Frequently Asked Questions (FAQ)

What's the price of HCW Biologics stock today?

One share of HCW Biologics stock can currently be purchased for approximately $3.16.
When is HCW Biologics's next earnings date?

Unfortunately, HCW Biologics's (HCWB) next earnings date is currently unknown.
Does HCW Biologics pay dividends?

No, HCW Biologics does not pay dividends.
How much money does HCW Biologics make?

HCW Biologics has a market capitalization of 15.08M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 57.72% to 2.84M US dollars. HCW Biologics made a loss 24.99M US dollars in net income (profit) last year or -$0.3 on an earnings per share basis.
What is HCW Biologics's stock symbol?

HCW Biologics Inc. is traded on the NASDAQ under the ticker symbol "HCWB".
What is HCW Biologics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of HCW Biologics?

Shares of HCW Biologics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are HCW Biologics's key executives?
HCW Biologics's management team includes the following people:
- Dr. Hing C. Wong Ph.D. Founder, Chief Executive Officer, Director & Sec.(age: 71, pay: $374,400)
- Ms. Rebecca Byam CPA, M.B.A. Chief Financial Officer(age: 69, pay: $286,000)
- Dr. Peter Rhode Chief Scientific Officer & Vice President of Clinical Operations(age: 67, pay: $228,500)
Is HCW Biologics founder-led company?

Yes, HCW Biologics is a company led by its founder Dr. Hing C. Wong Ph.D..
How many employees does HCW Biologics have?

As Jul 2024, HCW Biologics employs 45 workers, which is 2% more then previous quarter.
When HCW Biologics went public?

HCW Biologics Inc. is publicly traded company for more then 4 years since IPO on 20 Jul 2021.
What is HCW Biologics's official website?

The official website for HCW Biologics is hcwbiologics.com.
Where are HCW Biologics's headquarters?

HCW Biologics is headquartered at 2929 North Commerce Parkway, Miramar, FL.
How can i contact HCW Biologics?

HCW Biologics's mailing address is 2929 North Commerce Parkway, Miramar, FL and company can be reached via phone at +95 48 422 024.

HCW Biologics Inc.

hcwbiologics.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.

+95 48 422 024

2929 North Commerce Parkway
Miramar, FL 33025

CIK: 0001828673
ISIN: US40423R1059
CUSIP: 40423R105